Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.

Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Invest New Drugs. 2008 Jun; 26(3):233-9.

View in: PubMed

subject areas

Antineoplastic Combined Chemotherapy Protocols
Cytarabine
Drug Monitoring
Female
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid, Acute
Male
Maximum Tolerated Dose
Methemoglobinemia
Middle Aged
Pyridines
Recurrence
Thiosemicarbazones

authors with profiles

Mark Ratain
Mary Dolan
Olatoyosi Odenike
Richard A. Larson
Wendy Stock
Theodore Karrison